Regional Differences Across HTA and Procurement of Medtech Solutions: ‘Crossing the Pond’ of Differing Roles Across HTA and Procurement
Author(s)
Moderator: Richard Charter, MSc, Alira Health, London, LON, UK
Speakers: Arthi Chandran, MPH, MS, DrPH, ABBOTT, Santa Clara, CA, USA; Stephen Hull, MHS, Hull Associates LLC, Rockland, MA, USA; Myla Maloney, MBA, PINC AI™ Applied Sciences, Premier Inc., Matthews, NC, USA
Presentation Documents
Background: HTA for MedTech often does not lead to a funding/reimbursement mandate despite being a very robust manner of technology evaluation. When done correctly, HTA considerations include clinical, economic, and societal value to multiple stakeholder groups. There are isolated pockets where MedTech funding is attached to HTA, this is far from the norm most procurement decisions are still predominantly price driven. Initiatives such as value-based procurement, where the procurement decisions are made on clinical improvement and reduced total costs suggest HTA could be a very valuable resource for procurement decision making. We will discuss this paradigm in the context of an ISPOR MD&D SIG working group special project literature review and the future initiative to survey of HTA and procurement stakeholders.
Conference/Value in Health Info
Code
117
Topic
Economic Evaluation